Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A pharmaceutical composition containing miRNA-873 and its application

A technology of miRNA-873 and composition, which is applied in the field of biopharmaceuticals to achieve the effects of inhibiting myocardial ischemia damage, reducing myocardial infarction area and myocardial infarction area.

Inactive Publication Date: 2019-05-10
QINGDAO UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the signaling pathway of cardiomyocyte necrosis is still far from elucidated, and the pathway of miRNA in regulating the process of cardiomyocyte necrosis needs further study. Therefore, it is necessary to search for miRNAs that are specifically expressed in the heart and participate in cardiomyocyte necrosis, and to elucidate their mechanism of action. The diagnosis and treatment of heart disease based on miRNA has great significance and application prospects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical composition containing miRNA-873 and its application
  • A pharmaceutical composition containing miRNA-873 and its application
  • A pharmaceutical composition containing miRNA-873 and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Embodiment 1: myocardial ischemia and H 2 o 2 Detection of miRNA-873 expression during induced cardiomyocyte necrosis

[0016] This embodiment uses the experimental model of myocardial cell necrosis, and adopts the method established in this laboratory to cultivate the primary cardiomyocytes of rat suckling mice (rat suckling mice were purchased from Beijing Medical University, the rat strain is Wistar rats, rat suckling mice The preparation of primary cardiomyocytes can be found in the following literature: W.-Q.Tan, et al, Foxo3a Inhibits CardiomyocyteHypertrophy through Transactivating Catalase J Biol Chem.2008October 31; 283(44):29730-29739), 500uM H 2 o 2 Treat different times, extract RNA, and detect the expression level of miRNA-873 by real-time fluorescent quantitative PCR technology, such as figure 1 As shown in A, the expression level of miRNA-873 in H 2 o 2 Significantly down-regulated within 8h to 12h of induction.

[0017] In this embodiment, the rats...

Embodiment 2

[0018] Example 2: Experiment of miRNA-873 inhibiting cardiomyocyte apoptosis

[0019] In this example, primary cultured cardiomyocytes were used as a model. Transfect miRNA-873 pharmaceutical composition, miRNA-873 random sequence is used as control (ie NC), after 24 hours, use H 2 o 2 The cells were induced and treated for 12 hours, and the necrosis of cardiomyocytes was detected; the death of cardiomyocytes was detected by PI staining, and the results showed that overexpression of miRNA-873 could significantly inhibit H 2 o 2 induced cardiomyocyte apoptosis.

Embodiment 3

[0020] Example 3: Experimental verification of miRNA-873 overexpression inhibiting myocardial ischemia injury

[0021]Injection of the miRNA-873 pharmaceutical composition into the mice designed in this example can significantly inhibit myocardial ischemia-reperfusion injury. Taking C57 mice as the experimental subjects, the miRNA-873 pharmaceutical composition and miRNA-873 drug were injected according to the following method Composition negative control (NC), sham-operated mice were used as the control group, and C57 mice were used as the wild type. The mice were weighed and anesthetized, fixed in the supine position, sheared and disinfected with iodine; the trachea was cut midline in the neck and intubated, and the animal ventilator was used for positive pressure ventilation. Open the skin about 3 cm, bluntly separate the subcutaneous tissue and muscles layer by layer, open the chest, carefully lift the pericardium and cut it open to fully expose the heart; put 200 μL of th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of bio-pharmaceuticals and relates to a pharmaceutical composition containing miRNA-873 and application thereof. In a milliliter of the pharmaceutical composition containing miRNA-873, the content of 1,2-dioleoyl-3-trimethylaminepropane is 0.5-25mg, the molar ratio of miRNA-873 to 1,2-dioleoyl-3-trimethylaminepropane is 1:(150-205), the content of DC cholesterol is 0.1-5mg, the content of 1,2-dioleoyl-3-phosphatidyl ethanolamine is 0.1-20mg, the content of polyethylene glycol 2000 is 1-80mg, and the pharmaceutical composition also comprises the balance of phosphate buffer. The pharmaceutical composition is used for treating heart diseases such as myocardial infarction, myocardial ischemial injury, cardiac hypertrophy or myocardial fibrosis; and moreover, the pharmaceutical composition is simple in preparation process, obvious in drug effect, convenient to use and friendly in treatment environment.

Description

Technical field: [0001] The invention belongs to the technical field of biopharmaceuticals, and relates to a new drug of endogenous non-coding small RNA and its application, especially a pharmaceutical composition containing miRNA-873 and its application for preventing or treating heart disease. Background technique: [0002] Cardiovascular disease is a major threat to human health and life, and is the number one killer of human health. Worldwide, more than 17 million people die from cardiovascular disease every year, and its mortality rate is close to the sum of all cancer mortality rates; With the improvement of people's living standards and the change of diet structure, the mortality rate of cardiovascular diseases is on the rise, surpassing cancer as the number one cause of death. According to the latest statistical results recently released by the Ministry of Health, the prevalence of hypertension among residents aged 18 and over in my country is 18.8%, and it is estima...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K48/00A61P9/10A61P9/00
Inventor 王昆周露玙李培峰
Owner QINGDAO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com